ArticleClinical, cosmetic and investigational dermatology2026
A Successful Outcome of Upadacitinib Therapy in a Patient with Genital Erosive Fixed Drug Eruption: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fixed drug eruption (FDE) is a common cutaneous adverse drug reaction with limited effective treatments for severe genital erosive cases. This first reported case demonstrates the successful use of the selective Janus kinase 1 (JAK1) inhibitor upadacitinib as monotherapy for a severe, erosive FDE involving the genitalia. A 50-year-old male presented with rapidly progressing, painful erythema, erosions, and exudation on the scrotum and glans penis following drug intake, confirmed by histopathology. Treated solely with upadacitinib, the lesions achieved near-complete re-epithelialization by day 18, with no recurrence or adverse events during follow-up. This case highlights upadacitinib as a rapidly effective and well-tolerated novel therapeutic option for severe FDE in sensitive areas, addressing an unmet need and expanding the potential application of targeted Janus kinase (JAK) inhibition in cutaneous adverse drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.